UK receives 60 million doses of Novavax COVID-19 candidate vaccine
Published: August 14, 2020
By Alex Keown
BioSpace
Novavax has reached an agreement to supply the UK with 60 million doses of the vaccine if approved, as well as complex efficacy in the UK.
This morning, Novavax announced the agreement with the British that includes 60 million doses of NVX-CoV2373, the Novavax COVID-19 vaccine and a Phase III clinical trial to compare the effectiveness of the vaccine in the British population.
The NVX-CoV2373 is composed of a solid pre-melting protein manufactured with its patented nanoparticle generation and includes Novavax’s patented Matrix-M adjuvant. Knowledge of phase I/II of a Phase I/II exam showed that NVX-CoV2373 produced antibodies in healthy patients, a sign that the vaccine was working as expected. The vaccine was also well tolerated in those patients, the company said.
According to the announcement, the Phase III clinical trial will be a randomized, double-blind, placebo-controlled efficacy test in approximately 9,000 adults over the age of 18 to 85 in the UK. The trial is expected to begin in the third quarter of this year. with the UK government supporting and providing infrastructure to Novavax in the execution of the trial. The trial will evaluate NVX-CoV2373’s ability to oppose coVID-19 symptomatic disease and compare mobile T and antibody responses.
“We are revered as a spouse with the UK government to provide a vaccine that can provide significant coverage in the fight against the global fitness crisis,” Said Stanley C. Erck, President and CEO of Novavax in a statement. “Our Phase III clinical trial in the UK will be an essential detail when comparing the efficacy of NVX-CoV2373, which, in a Phase I trial, has already been shown to be well tolerated and has strong antibody responses. We are also excited to expand our collaboration with FUJIFILM Diosynth Biotechnologies to manufacture our antigen at its UK plant.
In addition to the agreement with the UK government, Novavax has expanded its collaboration with FUJIFILM Diosynth Biotechnologies concluded before this summer. FUJIFILM Diosynth will manufacture the antigenic component of NVX-CoV2373 on its Billingham, Stockton-on-Tees site in the United Kingdom, in addition to its sites in North Carolina and Texas in the United States. The FUJIFILM Diosynth Biotechnologies site in the UK is expected to produce approximately 180 million doses consistently with the year, further strengthening the global source of NVX-CoV2373 for other markets. A surplus source of antigen manufactured on the FUJIFILM Diosynth Biotechnologies site will be available for Novavax to sell to other markets outside the UK.
“To replace the pandemic course, FUJIFILM Diosynth Biotechnologies is pleased to expand our partnership with Novavax to manufacture its COVID-19 vaccine candidate on our UK site,” said Paul Found, Chief Operating Officer of FUJIFILM Diosynth Biotechnologies, a UK site. in a prayer. “We are honored with the British government and Novavax for the non-unusual purpose of providing a safe and effective vaccine to the British people.”
BioSpace Source:
https://www.biospace.com/article/u-k-government-secures-60-million-doses-of-novavax-experimental-covid-19-vaccine-candidate